UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009927
Receipt number R000011633
Scientific Title Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma
Date of disclosure of the study information 2013/02/01
Last modified on 2017/02/13 09:13:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma

Acronym

Immunomoduratory activity for MM treated with lenalidomide

Scientific Title

Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma

Scientific Title:Acronym

Immunomoduratory activity for MM treated with lenalidomide

Region

Japan


Condition

Condition

plasma cell myeloma

Classification by specialty

Medicine in general Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of the efficacy immunomodulatory activity for lenalidomide alone in relapse and refractory multiple myeloma

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

progression free survival time

Key secondary outcomes

safety, overall survival time, exploratory of immunomodulatory marker


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Treatment of lenalidomide

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

81 years-old >

Gender

Male and Female

Key inclusion criteria

1) relapse and refractory multiple myeloma without previously treated lenalidomide
2) Aged 20 to less than 81 years old
3) assessable M proteinemia or M proteinuira
4) ECOG PS 0-2
5) preserved mail organ function and implement the following criteria
a) neutrophil count is more than 1x10e9/L
b) platetel count is more than 5x10e10/L
c) Total bilirubin is less than three times-fold in upper limit
d) Serum AST and ALT are less than five times-fold in upper limit
e) Serum creatinine is less than 2.5mg/dl
f) ejection fraction in ultrasound cardiography is more than 50%
g) PaO2 is more than 60mmHg or SpO2 is more than 93%
6) promising more than 3 months living
7) menopausal female and male and female are enable to prevent conception by the adequate methods, including the surgical conception
8) complete informed concent

Key exclusion criteria

1) previously administered lenalidomide
2) hypersensitive reaction for lenalidomide, thalidomide and dexamethazone
3) non-secretory myeloma, solitary plasmacytoma, plasmacell leukemia and POEMS syndrome
4) CTCAE more than grade 3 neutropenia, thrombocytopenia
5) HBsAg is positive
6) HCV is positive, HIV is positive
7) uncontrollable liver dysfunction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetus mellitus, hypertension and infection
8) double cancer
9) psychoneurotic disorder, depression state or history
10) pregnant female, possible pregnancy or durling lactation
11) pulomonary fibrosis and interstitial pneumonitis interstitial shadow on chest CT, even if no sympton
12) physicians' decision

Target sample size

33


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shinya Kimura

Organization

Faculty of Medicine, Saga University

Division name

Hematology, Respiratory Medicine and Oncology

Zip code


Address

Nabeshima 5-1-1, Saga,Saga

TEL

0952-34-2366

Email

shkimu@cc.saga-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Noriyasu Fukushima

Organization

Faculty of Medicine, Saga University

Division name

Hematology, Respiratory Medicine and Oncology

Zip code


Address

Nabeshima 5-1-1, Saga,Saga

TEL

0952-34-2366

Homepage URL


Email

fukushin@cc.saga-u.ac.jp


Sponsor or person

Institute

Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University

Institute

Department

Personal name



Funding Source

Organization

Hematology, Respiratory Medicine and Oncology,Faculty of Medicine, Saga University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

佐賀大学医学部血液・呼吸器・腫瘍内科(佐賀県)、高木病院(福岡県)


Other administrative information

Date of disclosure of the study information

2013 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 01 Month 08 Day

Date of IRB


Anticipated trial start date

2013 Year 02 Month 01 Day

Last follow-up date

2014 Year 12 Month 31 Day

Date of closure to data entry

2015 Year 12 Month 31 Day

Date trial data considered complete

2015 Year 12 Month 31 Day

Date analysis concluded

2016 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2013 Year 02 Month 01 Day

Last modified on

2017 Year 02 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011633


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name